CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist.
about
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical AppraisalNew Insights into the Crossroads between EMT and Stemness in the Context of CancerCancer stem cells in small cell lung cancerCellular and molecular biology of small cell lung cancer: an overviewAdvances in Lung Stem Cells and Lung Cancer Stem CellsMolecular testing in lung cancer in the era of precision medicineOverexpression of secretagogin inhibits cell apoptosis and induces chemoresistance in small cell lung cancer under the regulation of miR-494High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cellsThe role of hypoxia on the acquisition of epithelial-mesenchymal transition and cancer stemness: a possible link to epigenetic regulationHistone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinomaTargeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factorsQuantitative mass spectrometric profiling of cancer-cell proteomes derived from liquid and solid tumors.Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activationTargeted therapy against cancer stem cells.Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.Inhibition of heat-shock protein 90 sensitizes liver cancer stem-like cells to magnetic hyperthermia and enhances anti-tumor effect on hepatocellular carcinoma-burdened nude mice.Arsenic trioxide inhibits cancer stem-like cells via down-regulation of Gli1 in lung cancer.DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive propertiesLong non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2.MBD3 inhibits formation of liver cancer stem cells.Smoking, inflammation and small cell lung cancer: recent developments.System analysis identifies distinct and common functional networks governed by transcription factor ASCL1, in glioma and small cell lung cancer.Pentapeptides for the treatment of small cell lung cancer: Optimisation by Nind-alkyl modification of the tryptophan side chainSmall cell lung cancer: Time to revisit DNA-damaging chemotherapy.Staurosporine analogs promote distinct patterns of process outgrowth and polyploidy in small cell lung carcinoma cells.Metastasis: an early event in cancer progression.Approaches for targeting cancer stem cells drug resistance.The Hedgehog Signaling Networks in Lung Cancer: The Mechanisms and Roles in Tumor Progression and Implications for Cancer Therapy.Concise Review: Emerging Drugs Targeting Epithelial Cancer Stem-Like Cells.Anti-Cancer Phytometabolites Targeting Cancer Stem CellsImmunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope.Mathematical Modeling of the Role of Survivin on Dedifferentiation and Radioresistance in Cancer.Uncovering the natural history of cancer from post-mortem cross-sectional diameters of hepatic metastases.Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition.Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling.A combination of valproic acid sodium salt, CHIR99021, E-616452, tranylcypromine, and 3-Deazaneplanocin A causes stem cell-like characteristics in cancer cells.Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.miR‑181b‑5p mediates TGF‑β1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer stem-like cells derived from lung adenocarcinoma A549 cells.Long non-coding RNA TUG1: a novel therapeutic target in small cell lung cancer.
P2860
Q26744536-CB7985B9-E1B1-4DD8-873E-1A25E7D283C1Q26764831-C1AAD0DA-3768-43B2-A96A-5974FCB9BA27Q26767026-D0C50005-A2E1-4903-9D06-39332AE6B9D4Q26767029-9588DF79-C275-491C-9757-8CBB345584D0Q26781688-F4A2B3AE-65AF-43E0-8A0A-2E2E279EC1C9Q26824599-8492577D-45AC-41A3-963E-819FD88E79D5Q28396088-ECB41662-0623-427E-8B0C-6719A6031038Q29249058-BF0DBB9D-E8D6-44E9-B7AD-AFD09B536BCDQ33907274-3F684103-63E6-45C8-A89B-C884C7D9C677Q34287415-A14D3AC0-D633-4773-B2E3-85191882B33DQ35545648-1624AB22-E115-4CFA-BD75-34610AB9AED5Q35600155-BEADF252-5648-47E7-9752-161256D1812FQ35655447-59EEB35B-5B13-4EC5-ACFC-BDCEE39A65CAQ35713579-9C0C2FB4-BE87-40BC-A589-695158638674Q35802983-69B5E53B-3BAB-4253-A04B-436D23BD2C45Q36035933-EF5EA756-DA11-4006-A026-F2A8FD05E561Q36368005-E9456CF6-6383-485E-AE16-D5AC3F177BBAQ36841351-6321090B-9D78-411E-A1FD-5FB97B1FACD7Q37426768-14B7D7E1-492D-4FA6-A21A-10FCEAA184CAQ37576353-05293AD8-132E-4DF0-866A-A459F489EEB2Q37701541-AFABFEEE-139E-41D3-99DB-91C9BD347733Q38569752-6220061E-EE0C-4AC8-ACCD-CD73BA4C0652Q38696402-F10607BE-CEA5-476D-8C09-A9140EEC2882Q38700858-3AF93973-3B24-45AB-A4F9-287B870C9EF8Q38888068-1D3BA6E7-94EC-4205-91D1-3638D284AB35Q38930827-5B2DC4C1-05F6-422C-A005-72DF147C522FQ38968225-ECE25124-D3A1-4011-8AF4-BEDB166ADF2EQ38971795-8866E278-04E7-441F-9F5A-57F81D6DC2AAQ39096007-78746FA1-3B6D-40CB-9FC7-6A91137E1E4FQ39112034-2A3A63C5-2A60-48AA-8313-7451516D9FBEQ39214227-C8915769-459D-4087-B575-A614343A0239Q39393217-89EBFD51-0F47-49B6-8D55-269047396056Q39704104-0971096D-AEDB-40EA-ABA9-4C99E1E2A221Q40664307-33251EFB-1A04-4155-9974-62934319665DQ40962722-C8CA44F0-BD63-418F-B95E-EE9C9D685B33Q41083994-65D65E27-2C0C-4D90-9573-C55728CADF15Q41593141-4287EAD2-FC6D-49A1-A21C-5DC7EE054032Q41900139-2DD1868F-2A6E-4356-B733-034273F4CE4FQ42207693-81A95A97-DD92-4A2B-93A3-45A5D7B71BB2Q42341995-6314CCE4-C540-4447-AEED-0341D2190B4A
P2860
CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
CD133+ cancer stem-like cells ...... novel neuropeptide antagonist.
@en
CD133+ cancer stem-like cells ...... novel neuropeptide antagonist.
@nl
type
label
CD133+ cancer stem-like cells ...... novel neuropeptide antagonist.
@en
CD133+ cancer stem-like cells ...... novel neuropeptide antagonist.
@nl
prefLabel
CD133+ cancer stem-like cells ...... novel neuropeptide antagonist.
@en
CD133+ cancer stem-like cells ...... novel neuropeptide antagonist.
@nl
P2093
P50
P1433
P1476
CD133+ cancer stem-like cells ...... novel neuropeptide antagonist.
@en
P2093
Alison C Mackinnon
Doris M Rassl
Mark Bradley
Nicolaos Avlonitis
Sana Sarvi
Tariq Sethi
P304
P356
10.1158/0008-5472.CAN-13-1541
P407
P577
2014-01-16T00:00:00Z